Novigenix, a force in innovative cancer diagnostics, has announced a landmark partnership with the IMMUcan Consortium, a European leader in cancer research.
In order to find out, OSP sat down with Brigham Hyde to ask him a number of questions about the company's technology and what it is doing to upgrade traditional trial methods.
With the FDA issuing guidance on more diversity within clinical trials, it is a subject many companies are being encouraged to focus on, each with their own approach.
The health data company emerges promising to revolutionize the real-world data made available to clinical researchers, and to provide the data to the patients themselves.
The two companies will combine real-world datasets to better understand marketing treatment with Bristol Myers Squibb’s drug in a post-marketing setting.
Experts from the health information specialist explain how the use of RWD and RWE has helped speed up and improve the development of therapies and vaccines.
An expert from trial tech specialist Komodo Health talks about how real-world evidence use could elevate study design, conserve costs, and improve recruitment.
Cloud-based Clarify Trials is real-world evidence-based software intended to improve recruitment of clinical study patients from underrepresented communities.
The two companies, along with Datavant, will combine real-world data and decentralized platforms to yield better patient information management and insights.
The company has released a survey of cancer doctors; 83% of those polled believe real-world data is crucial to accelerating cancer research and treatment.
An epidemiologist from the healthcare data specialist offers perspective on how real-world data can help get to the heart of long-lasting COVID research.
A leader from Firma Clinical Research advises that while using RWD can be daunting, putting the data to use can lead to a number of notable advantages.
Cota has released a survey revealing about two-thirds of cancer patients and their families are unsatisfied at the speed of cancer treatment development.
According to a leader from CRO Quanticate, the research industry’s increased use of real-world data is leading to a broad range of benefits in trial work.
The research collaboration is aimed at studying disparities in care with a focus on multiple myeloma, a cancer disproportionately affecting Black patients.
The UK-based development and research firm hopes to accelerate patient access to psychedelic therapies for treatment of various mental health conditions.
A leader from the global CRO talks about how use of RWE in clinical trials can benefit research sites and sponsors, and satisfy regulatory requirements.
TriNetX is a new technology partner working on the FDA’s Sentinel System, led by HPHCI, which has signed a contract worth up to $220m to develop a new Sentinel Innovation Center.
Beacon of Hope CRO is working with sponsors and other service providers to design Right to Try treatment programs, which the company’s founder says have ‘unmatched’ flexibility, an ability to treat screen fails and create ‘interim clinical milestones,’...
Parexel increases its real world data network by more than 330m patients across 60 health care and consumer sources though a partnership with HealthVerity – which earlier this year raised $25m to advance its technology.
The Friends of Cancer Research, in collaboration with Iqvia and other health care research organizations, are working to determine where and when real-world data can be trusted.
PCRF has selected Datavant to de-identify and link patient data across its clinical research network, which will ‘empower’ medical researchers while protecting patient privacy.
Medable joins the AHA’s ‘Innovators Network’ to develop the Human Heart Digitome, which is expected to be the largest real-world database dedicated to advancing cardiovascular disease research and patient care, says CEO.
Belong.Life raises $14m as part of a Series B funding round with plans to expand its patient engagement platform, using and complementing Iqvia’s solutions “to transform patient engagement,” says Iqvia VP.
Iqvia leads the real world evidence market, which is at an inflection point, as pharma furthers its investment and vendors improve capabilities, according to a recent report.
Clinical AI, no matter how sophisticated, cannot work on its own, says Life Image CEO, who predicts that CROs will either adapt or be disrupted by smaller companies with digital access capabilities.
By Barbara Lopez Kunz, global chief executive, DIA
The practice of incorporating the voice of the patient into clinical development has gained significant traction over the past decade, and rightfully so.
University Hospitals Cleveland Medical Center has joined the TriNetX network to increase its research opportunities while benefitting the network of real world evidence and data.
The biopharma industry is on the precipice of making personalized medicine a reality with access to massive amounts of data, computing power, and artificial intelligence to run in silico clinical trials, says GNS Healthcare CEO.
By Pamela Tenaerts, executive director, Clinical Trials Transformation Initiative (CTTI)
We entered 2018 with a solid foundation in place for building better, more efficient clinical trials. Throughout the year, progress – particularly in the areas of mobile technologies, real-world evidence, and patient engagement – resulted in new, tangible...
The new year will bring more data than the last 500 decades, information that will be used to improve clinical trial design and shorten drug development timelines, say industry experts.
TriNetX announced it will add claims data from 190m patients to its network, including ambulatory care, medical claims, and pharmacy claims, to enable researchers to query and analyze the information.
Parexel is adopting Medidata’s Shyft Analytics platform to bolster its real-world evidence generation and outcomes research offering to biopharmaceutical and medical device clients.
PRA Health Sciences is looking at and assessing various opportunities using real world data – as the company has become reliant on data as part of its clinical process, says CEO.
Cytel examines the gap between controlled experiment and real-world data at a time when the industry is collecting more data from more sources than ever before.
To improve clinical trial design, site selection, and patient enrollment, the real-world data solutions firm Clinerion is partnering with Patient iP, a health data and analytics company.
